RS32204A - Čvrsta formulacija leka za derivat piperazinuree - Google Patents

Čvrsta formulacija leka za derivat piperazinuree

Info

Publication number
RS32204A
RS32204A YU32204A YUP32204A RS32204A RS 32204 A RS32204 A RS 32204A YU 32204 A YU32204 A YU 32204A YU P32204 A YUP32204 A YU P32204A RS 32204 A RS32204 A RS 32204A
Authority
RS
Serbia
Prior art keywords
methyl
drug formulation
ureido
phenoxy
carbonyl
Prior art date
Application number
YU32204A
Other languages
English (en)
Serbian (sr)
Inventor
Heiko Kranz
Christoph Volkel
Ralph Lipp
Johannes Tack
Herbert Wiesinger
Original Assignee
Schering Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Aktiengesellschaft filed Critical Schering Aktiengesellschaft
Publication of RS32204A publication Critical patent/RS32204A/sr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1635Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
YU32204A 2001-10-18 2002-10-07 Čvrsta formulacija leka za derivat piperazinuree RS32204A (sr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10152351A DE10152351B4 (de) 2001-10-18 2001-10-18 Feste Arzneimittelformulierung für ein Piperazinharnstoffderivat
PCT/EP2002/011229 WO2003035037A1 (de) 2001-10-18 2002-10-07 Feste arzneimittelformulierung für ein piperazinharnstoffderivat

Publications (1)

Publication Number Publication Date
RS32204A true RS32204A (sr) 2006-10-27

Family

ID=7703496

Family Applications (1)

Application Number Title Priority Date Filing Date
YU32204A RS32204A (sr) 2001-10-18 2002-10-07 Čvrsta formulacija leka za derivat piperazinuree

Country Status (23)

Country Link
EP (1) EP1435917A1 (pl)
JP (1) JP2005506365A (pl)
KR (1) KR20040047920A (pl)
CN (1) CN1571660A (pl)
AR (1) AR037111A1 (pl)
AU (1) AU2002333896B2 (pl)
BR (1) BR0213340A (pl)
CA (1) CA2463951A1 (pl)
CO (1) CO5580740A2 (pl)
DE (1) DE10152351B4 (pl)
EC (1) ECSP045108A (pl)
HR (1) HRP20040435A2 (pl)
IL (1) IL161166A0 (pl)
MX (1) MXPA04003522A (pl)
NO (1) NO20042022L (pl)
NZ (1) NZ532287A (pl)
PE (1) PE20030472A1 (pl)
PL (1) PL367987A1 (pl)
RS (1) RS32204A (pl)
RU (1) RU2311172C2 (pl)
UY (1) UY27500A1 (pl)
WO (1) WO2003035037A1 (pl)
ZA (1) ZA200403781B (pl)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1990469A (zh) 2001-06-27 2007-07-04 史密丝克莱恩比彻姆公司 作为二肽酶抑制剂的氟代吡咯烷
EP1749519A1 (de) * 2005-08-05 2007-02-07 Schering Aktiengesellschaft Arzneiform mit Retardtierter pH-unabhängiger Wirkstofffreisetzung für Wirkstoffe mit starker pH-abhängiger Löslichkeit
JP5826456B2 (ja) * 2006-04-26 2015-12-02 アルファファーム ピーティーワイ リミテッド コーティングされていない分離したユニットおよび延長放出マトリクスを含む制御放出配合物
DE102008047910A1 (de) 2008-09-19 2010-03-25 Molkerei Meggle Wasserburg Gmbh & Co. Kg Tablettierhilfsstoff auf Laktose- und Cellulosebasis
KR101654582B1 (ko) 2016-05-12 2016-09-06 그린로드(주) 원뿔형 부유 고분자 필터, 및 그의 제조장치 및 제조방법, 및 그를 포함하는 수처리 필터
RU2729223C1 (ru) * 2020-05-13 2020-08-05 Мераб Георгиевич Чикобава Дозированная форма для амплификации нуклеиновых кислот

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1246383B (it) * 1990-04-17 1994-11-18 Eurand Int Metodo per il mascheramento del sapore di farmaci
FR2668945B1 (fr) * 1990-11-12 1993-02-19 Theramex Nouveau procede de cristallisation des substances organiques et les composes ainsi obtenus.
US5705190A (en) * 1995-12-19 1998-01-06 Abbott Laboratories Controlled release formulation for poorly soluble basic drugs
US6004996A (en) * 1997-02-05 1999-12-21 Hoffman-La Roche Inc. Tetrahydrolipstatin containing compositions
US6207665B1 (en) * 1997-06-12 2001-03-27 Schering Aktiengesellschaft Piperazine derivatives and their use as anti-inflammatory agents
EA003137B1 (ru) * 1998-02-05 2003-02-27 Пфайзер Продактс Инк Новые производные дигидроксигексановой кислоты
EP1027885B1 (en) * 1999-02-09 2008-07-09 Pfizer Products Inc. Basic drug compositions with enhanced bioavailability

Also Published As

Publication number Publication date
MXPA04003522A (es) 2004-07-23
AU2002333896B2 (en) 2007-07-26
ECSP045108A (es) 2004-06-28
RU2004115328A (ru) 2005-06-10
PE20030472A1 (es) 2003-06-16
UY27500A1 (es) 2003-06-30
DE10152351B4 (de) 2005-09-22
KR20040047920A (ko) 2004-06-05
JP2005506365A (ja) 2005-03-03
EP1435917A1 (de) 2004-07-14
AU2002333896A2 (en) 2003-05-06
AR037111A1 (es) 2004-10-20
CA2463951A1 (en) 2003-05-01
RU2311172C2 (ru) 2007-11-27
WO2003035037A1 (de) 2003-05-01
CO5580740A2 (es) 2005-11-30
DE10152351A1 (de) 2003-05-08
NO20042022L (no) 2004-05-14
PL367987A1 (pl) 2005-03-21
BR0213340A (pt) 2004-10-05
CN1571660A (zh) 2005-01-26
IL161166A0 (en) 2004-08-31
HRP20040435A2 (en) 2005-06-30
ZA200403781B (en) 2004-11-29
NZ532287A (en) 2007-04-27

Similar Documents

Publication Publication Date Title
EP0173210B1 (de) Pellet-Zubereitung
JP6976946B2 (ja) 生理活性の強い、urat1のインヒビターを含む医薬組成物
JPWO2008149894A1 (ja) セルロース系微小核粒子及びその製造方法
CA2858478C (en) Disintegrant-free delayed release doxylamine and pyridoxine formulation and process of manufacturing
RS66060B1 (sr) Sastav koji sadrži ramipril i indapamid
WO2005117896A1 (de) Formulierungen, die fasudil, eine matrix und einem mantel enthalten
HU227490B1 (en) Sustained release pharmaceutical preparation containing carvedilol
RS32204A (sr) Čvrsta formulacija leka za derivat piperazinuree
CA2781826A1 (en) Controlled release pharmaceutical compositions of galantamine
AU2025202455A1 (en) Pharmaceutical composition of darolutamide
JP2017075139A (ja) 低用量薬物を含有する口腔内崩壊錠
ITMI950961A1 (it) Composizioni farmaceutiche contenenti gemfibrozil
US20030087913A1 (en) Solid pharmaceutical agent formulation for a piperazine urea derivative
EP2838518B1 (en) Method of treating acne
Torrado et al. Tableting of multiparticulate modified release systems
JP2007332074A (ja) 口腔内速崩壊錠およびその製造方法
Yoshida A novel gastroretentive floating system for zidovudine, based on calcium-silicate beads
JP6002870B1 (ja) 低用量薬物を含有する口腔内崩壊錠
AU2006335344A1 (en) Controlled release formulation of divalproic acid and its derivatives
Alany Oral Modified Release Multiple-Unit Particulate Systems: Compressed Pellets, Microparticles and Nanoparticles
US20140309198A1 (en) Method of treating acne